Flt2-13T

General Information


DRACP ID  DRACP05001

Peptide Name   Flt2-13T

Sequence  STNITVTLKKFPL

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic 

Disulfide/Other Bond  Native peptide

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C68H116N16O19

Absent amino acids  ACDEGHMQRWY

Common amino acids  T

Mass  167598

Pl  10.81

Basic residues  2

Acidic residues  0

Hydrophobic residues  5

Net charge  2

Boman Index  -707

Hydrophobicity  25.38

Aliphatic Index  112.31

Half Life 
  Mammalian: 1.9 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 11311231

Title  A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor

Doi 10.1016/s0014-5793(01)02314-6

Year  2001

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.